Loading...
Home 2017-04-13T01:43:52+00:00

What do we do?

Our work allows cancer drugs to be efficiently produced, and delivered to cancerous tumors in a targeted fashion that doesn’t destroy the patient’s normal healthy cells indiscriminantly. We do this by simplifying and standardizing the production of antibody drug conjugates to treat cancer, using proprietary site-selective chemistries as protein modification technologies.

Who are we?

We are established scientists and medical professionals determined to treat people around world with superior, targeted cancer therapeutics.

Partnership opportunities

Leverage our novel chemistries to create your superior targeted therapeutics to treat cancer.

Investment opportunities

We have two parallel development paths: platform technology with the ability to be licensed by others and our own proprietary therapeutic products to treat cancer

Latest News and Events

ADVANCED PROTEOME THERAPEUTICS EXPANDS ANTIBODY-DRUG CONJUGATE COLLABORATION

  Vancouver, British Columbia / November 20, 2017 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) a biotechnology company focused on developing superior targeted protein therapeutics, is expanding the collaboration with the National Research Council of Canada (NRC) and receiving support from its Industrial Research [...]

December 6th, 2017|

We just moved into JLABS@Toronto

Advanced Proteome Therapeutics Corporation has offices in Canada at JLABS@Toronto and in Boston.